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Abstract
Lymphangioleiomyomatosis (LAM), a multisystem disease of women, is manifest by the proliferation of smooth muscle-like
cells in the lung resulting in cystic lung destruction. Women with LAM can also develop renal angiomyolipomas. LAM is
caused by mutations in the tuberous sclerosis complex genes (TSC1 or TSC2), resulting in hyperactive mammalian Target of
Rapamycin (mTOR) signaling. The mTOR inhibitor, Rapamycin, stabilizes lung function in LAM and decreases the volume of
renal angiomyolipomas, but lung function declines and angiomyolipomas regrow when treatment is discontinued,
suggesting that factors induced by mTORC1 inhibition may promote the survival of TSC2-deficient cells. Whether microRNA
(miRNA, miR) signaling is involved in the response of LAM to mTORC1 inhibition is unknown. We identified Rapamycin-
dependent miRNA in LAM patient angiomyolipoma-derived cells using two separate screens. First, we assayed 132 miRNA
of known significance to tumor biology. Using a cut-off of .1.5-fold change, 48 microRNA were Rapamycin-induced, while 4
miRs were downregulated. In a second screen encompassing 946 miRNA, 18 miRs were upregulated by Rapamycin, while
eight were downregulated. Dysregulation of miRs 29b, 21, 24, 221, 106a and 199a were common to both platforms and
were classified as candidate ‘‘RapamiRs.’’ Validation by qRT-PCR confirmed that these microRNA were increased. miR-21, a
pro-survival miR, was the most significantly increased by mTOR-inhibition (p,0.01). The regulation of miR-21 by Rapamycin
is cell type independent. mTOR inhibition promotes the processing of the miR-21 transcript (pri-miR-21) to a premature
form (pre-miR-21). In conclusion, our findings demonstrate that Rapamycin upregulates multiple miRs, including pro-
survival miRs, in TSC2-deficient patient-derived cells. The induction of miRs may contribute to the response of LAM and TSC
patients to Rapamycin therapy.
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Introduction
Lymphangioleiomyomatosis (LAM) is a devastating multi-
system disease that almost exclusively affects women and can
result in end-stage lung disease. LAM is characterized by the
diffuse proliferation of smooth muscle-like cells (LAM cells) that
express melanocyte lineage proteins. In the lungs, LAM cells can
lead to small airway obstruction, blockage of lymphatic vessels
leading to the formation of chylous pleural effusions, and cystic
parenchymal destruction which is believed to be due to the release
of matrix metalloproteinases and other catabolic enzymes [1,2].
LAM occurs in two forms: in association with germline mutations
in the tuberous sclerosis complex (TSC) genes, and in women who
do not have tuberous sclerosis (sporadic LAM). The majority of
women with TSC-LAM and about 40% of women with sporadic
LAM have renal angiomyolipomas, which are benign tumors
consisting of smooth muscle, fat and dysplastic vasculature.
Angiomyolipoma cells have many similarities to LAM cells and
may arise from a common progenitor cell [3]. LAM cells from
women with sporadic LAM can carry somatic mutations in the
TSC2 gene, which is a tumor suppressor gene that regulates the
mammalian Target of Rapamycin (mTOR) [4,5,6,7,8].
mTOR is a kinase that integrates cellular and environmental
cues, including growth factor activity and glucose levels, to
regulate cell growth and proliferation. mTOR exists in two distinct
complexes: mTOR complex 1 (mTORC1), which includes
Raptor, and mTOR complex 2, which includes Rictor [9,10].
Recent clinical trials of allosteric mTORC1-inhibitors such as
Sirolimus (Rapamycin) in women with LAM have been promising
in that they confer a partial reduction in angiomyolipoma volume
and stabilization of lung function [11,12]. However, upon
cessation of therapy lung function decline resumes and angiomyo-
lipomas regrow, suggesting that allosteric mTORC1 inhibitors
exert a cytostatic but not cytotoxic effect.
MicroRNA (miRNA or miRs) are small RNA molecules that
regulate gene expression, primarily by affecting transcript stability.
Many miRNA have their own promoter regions and undergo
transcription in a tightly regulated manner. Mature miRNA form
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e60014a RNA-induced silencing complex (RISC) with chaperone
proteins, binding to the 39 untranslated region of mRNA to either
promote transcript degradation or repress protein translation.
Over 1000 miRNA species have been identified, each with the
ability to regulate hundreds of genes; moreover the 39UTR of
individual genes can recognize multiple miRNAs and mRNAs of
differing abundance can ‘‘compete’’ for miRNA binding and
consequent silencing [13].
Given the increasing evidence that microRNA participate in the
pathogenesis of malignancies, inflammatory bowel disease,
cardiomyopathies, and lung diseases including asthma, pulmonary
hypertension and idiopathic pulmonary fibrosis [14,15,16,17,18],
we explored whether dysregulated miRNA expression is associated
with mTORC1 activity in LAM and TSC. We utilized TSC2-
deficient LAM patient-derived cells with hyperactive mTORC1
and two different miRNA screens to identify ‘‘RapamiRs’’-
miRNA that are modulated by the mTORC1-inhibitor, Rapa-
mycin. Using qRT-PCR, we confirmed the dysregulation of six
miRs by Rapamycin and focused our attention on miR-21, which
is a known ‘‘oncomiR.’’ Interestingly, miR-21 induction by
Rapamycin appears to be TSC2-independent.
Our results demonstrate that Rapamycin promotes the expres-
sion of several miRNA species, which we term ‘‘RapamiRs,’’ in
cellular models of LAM. Of the RapamiRs identified in our
screens, miR-21, which has pro-survival effects in many cell types,
is the most strongly induced by Rapamycin. To our knowledge,
this is the first unbiased identification of mTORC1-dependent
miRNA in human cells. Manipulation of pro-survival mTORC1-
dependent miRNA may prove to be a valuable adjunct to
Rapamycin therapy for TSC and LAM patients. RapamiRs may
also have relevance to the broad range of human diseases that are
associated with activation of mTORC1, including the majority of
human malignancies.
Results
High-throughput screening identifies Rapamycin-
dependent microRNA
To determine whether Rapamycin regulates miRNA, we
performed two unbiased miRNA screens using LAM patient-
derived 621-101 cells as an in vitro model of LAM (Tables 1, 2).
These cells were derived from the angiomyolipoma of a woman
with the sporadic form of LAM and carry bi-allelic inactivation of
the TSC2 gene [19]. An identical TSC2 mutation (R611Q) was
present in this patient’s pulmonary LAM cells [5]. 621-101 cells,
cultured in DMEM containing 10% FBS, were treated with the
allosteric mTOR inhibitor, Rapamycin (20 nM, 24 hours) or with
vehicle control (DMSO). Isolated RNA was applied to a Signosis
microRNA platform which assays 132 cancer-specific human
miRNA by ligating two complementary tagged DNA probes to
each target miRNA and hybridizing the complexes to a
nitrocellulose membrane. Each target is assayed in duplicate and
normalized to the expression of RNU48, a small nucleolar RNA
molecule commonly used for normalization of miRNA levels [20].
The western blot in Figure 1A shows the level of phospho-S6
downregulation with rapamycin treatment. Nineteen miRNA
were induced more than 2-fold, with miRs- 29b, 22, 26a, 199b and
181a being most highly increased. Four miRs - 375, 488, 142-5p,
and 368 - were downregulated (Figure 1B). These results point
toward a previously unknown miR-regulated signaling network
downstream of mTORC1 with the potential to impact the
expression of hundreds of mRNA in a cell-type dependent
manner. We termed these Rapamycin-dependent miRs ‘‘Rapa-
miRs.’’
To further investigate this putative RapamiR network, we
performed a second, broader screen using the Exiqon platform,
which incorporates locked-nucleic acid technology to increase
probe-target specificity. This platform assays 946 human miRNA
in quadruplet, including all known human miRNA listed in
miRBase (version 15.0, http://mirbase.org/). A pool of three
biological replicates was used for each sample. Results were
normalized to RNU44. Interestingly, only 18 miRNAs were
upregulated .1.5-fold (Figure 2), versus 19 miRNA upregulated
.2 fold and 48 upregulated .1.5 fold in the Signosis array
(Figure 1), despite the fact that the Signosis array contained fewer
miRNA. miRs 29b, 31, 29a, 222 and 300 were among the most
strongly induced miRNA using the Exiqon platform; 8 miRs were
downregulated .1.5 fold.
Upregulation of miRNA 29b, 21, 24, 221, 106a and 199a was
common to both the Signosis and Exiqon platforms. Of the miRs
assayed in the Exiqon array that were not included in the Signosis
array, Rapamycin promoted a .1.5-fold induction of miR-31,
222, 300, 1973, 886-5p, 886-3p, 23 and 214 and a .1.5-fold
repression of miRs 210, 451, 513 and 1275.
The miRs that were dysregulated in both screens (miRs- 29b,
21, 24, 221, 106a and 199a) were included in a set selected for
qRT-PCR confirmation. We also included miR-31 and miR-210,
which were among the twelve miRNA dysregulated in the Exiqon
array but not included in the Signosis array. miR-31, which was
upregulated by Rapamycin, is anti-tumorigenic, preventing
metastasis in models of breast cancer [21,22], and miR-210,
which was downregulated by Rapamycin, is a well-described
hypoximiR [23,24,25]. HypoximiRs are upregulated during
hypoxia and have been shown to promote angiogenesis and
smooth muscle proliferation. We first confirmed that similar levels
of RapamiRs were observed using either RNU44 or RNU48 to
normalize miRNA expression (Figure 3A). Three different
biological replicates were used for the confirmation studies and
miRNA expression was normalized to RNU48. MiRNA 21, 24, 31
and 221 were induced by Rapamycin .1.5-fold, consistent with
the array results, with miR-21 being the most highly induced
(Figure 3B). MiR-210 was decreased .1.5-fold, again consistent
with the array results (Figure 3B).
Rapamycin induces miR-21 expression in multiple TSC2-
deficient cell types and miR-21 expression may be TSC2-
independent
To identify whether miR-21 is regulated by Rapamycin and/or
TSC2 in other cell lines, tuberin (TSC2) was stably downregulated
in C3H-10T1/2 mouse pre-pericyte fibroblasts with a lentiviral
shRNA vector (Figure 4A). Cells were cultured in DMEM
containing 10% FBS and treated with Rapamycin (20 nM) or
control for 24 hours. Rapamycin increased miR-21 levels
approximately 2-fold in both tuberin-deficient and control shRNA
cells (Figure 4B), but unexpectedly no decrease in miR-21 was
observed in the cells with tuberin downregulation despite the
increased phosphorylation of ribosomal protein S6, a downstream
target of mTORC1. Next, we utilized Tsc2-null mouse embryonic
fibroblasts and ELT3 cells (Tsc2-null cells from an Eker rat uterine
leiomyoma), which are established cellular models of TSC
[26,27,28] compared to HEK293 and A549 cells, which express
TSC2. Cells were cultured in DMEM containing 10% FBS and
treated with Rapamycin (20 nM, 24 h) versus vehicle control. The
human cells were normalized to RNU44, murine cells to
snoRNA202, and rat cells to U87. miR-21 was induced .1.5-
fold (p,0.05, n=3) by Rapamycin in each of these cell lines
(Figure 4C). These results further confirm that miR-21 is induced
MicroRNA in TSC and LAM
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that the regulation of miR-21 may be TSC2-independent.
Rapamycin regulates miR-21 levels independently of AKT
signaling
TSC2-null cells display feedback inhibition to the PI3K/AKT
signaling pathway via hyperactivation of mTORC1 [29,30].
When TSC2-null cells are treated with Rapamycin this feedback
inhibition is released and AKT is phosphorylated and activated.
To determine whether Rapamycin regulates miR-21 expression
via an AKT-dependent mechanism, we treated 621-101 cells with
Rapamycin and the AKT inhibitor MK2206 (Selleckchem,
Catalog No. S1078) (Figure 5). In Figure 5A (lanes 1–2), western
blot analysis was performed to confirm that p-AKT levels are
Table 1. Rapamycin-regulated miRNA in LAM patient-derived cells identified by the Signosis Array (Fold Change .1.5).
miRNA
Fold Change (Rapa 24 h/
DMSO miRNA
Fold Change (Rapa 24 h/
DMSO) miRNA
Fold Change (Rapa 24 h/
DMSO)
miR-29b 4.47 miR-206 2.21 miR-10a 1.63
miR-22 2.99 miR-224 1.97 miR-136 1.62
miR-26a 2.95 miR-125a 1.95 miR-182 1.62
miR-199b 2.93 miR-106b 1.92 miR-188 1.62
miR-181a 2.82 miR-154 1.88 miR-221 1.60
miR-30b 2.69 miR-9 1.87 miR-34a 1.59
miR-19a 2.64 miR-21 1.85 miR-181d 1.58
miR-125b 2.52 miR-204 1.85 miR-20a 1.57
miR-137 2.48 miR-9-1 1.83 miR-10b 1.57
miR-181b 2.47 Let-7b 1.80 miR-126 1.57
miR-181c 2.47 miR-140 1.76 miR-30c 1.56
miR-30a-5p 2.47 miR-106a 1.74 miR-131 1.56
miR-17-3p 2.44 miR-30a-3p 1.72 miR-17-5p 1.53
miR-197 2.30 miR-24 1.71 miR-368 0.67
miR-199a 2.30 miR-135b 1.70 miR-142-5p 0.65
miR-183 2.29 miR-141 1.70 miR-488 0.56
miR-18a 2.23 miR-19b 1.70 miR-375 0.54
miR-95 2.21
doi:10.1371/journal.pone.0060014.t001
Table 2. Rapamycin-regulated miRNA in LAM patient-derived cells identified by the Exiqon Array (Fold Change .1.5, normalized
to RNU44).
microRNA Expression Change (Rapamycin/DMSO) microRNA Expression Change (Rapamycin/DMSO)
miR-29b 2.65 miR-1274 0.67
miR-31 2.64 miR-210 0.67
miR-29a 2.15 miR-451 0.64
miR-222 2.14 miR-1285 0.62
miR-300 2.13 miR-1308 0.62
miR-21 2.07 miR-1908 0.58
miR-1973 1.97 miR-513a-5p 0.43
miR-221 1.91 miR-1275 0.42
miR-886-5p 1.86
miR-24 1.82
miR-574 1.73
miR-106a 1.62
let-7d 1.57
mir-886-3p 1.55
miR-23b 1.53
miR-214 1.53
doi:10.1371/journal.pone.0060014.t002
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compared to DMSO treated cells. Additionally, we confirmed that
MK2206 (10 nM, 24 h) inhibited AKT phosphorylation at S473
when 621-101 cells were treated with Rapamycin and MK2206.
In Figure 5B, we analyzed miR-21 levels in the same 621-101 cell
samples used for western blot. miR-21 levels were upregulated by
Rapamycin and unaffected by AKT inhibition (compare blue bar
to purple bar). These results indicate that miR-21’s regulation by
Rapamycin is AKT-independent in 621-101 cells.
Rapamycin potentiates the post-transcriptional
processing of pri-miR-21
MiRNA biogenesis is a tightly regulated process, with key
enzyme complexes participating in transcription and processing at
three major junctions (Figure 6A). Post-transcriptional processing
is a key mechanism to controlling miRNA levels [31]. The
regulation of miR-21, in particular, has been well-characterized,
with Davis and colleagues demonstrating that TGF-beta and
Smad signaling induces a Drosha-mediated post-transcriptional
processing of pri-miR-21 to induce miR-21 expression [32]. To
determine whether Rapamycin influences the processing of pri-
miR-21, we treated 621-101 cells, cultured in DMEM containing
10% FBS, with Rapamycin (20 nM) or DMSO for 24 hours and
assayed the expression of pri-miR-21, pre-miR-21 and miR-21
using qRT-PCR. Rapamycin significantly induced pre-miR-21
and miR-21 at 24-hours, but did not affect expression of pri-miR-
21 (Figure 6B). This result suggests that Rapamycin potentiates
the DROSHA-mediated processing of pri-miR-21.
Discussion
The landmark Multicenter International LAM Efficacy of
Sirolimus (MILES) Trial, a randomized, placebo controlled trial in
89 women with sporadic or TSC-associated LAM, demonstrated
that Rapamycin (an allosteric mTOR inhibitor) stabilized lung
function during one year of therapy; discontinuation of therapy
resulted in a rate of lung function decline similar to untreated
patients [12]. These findings are consistent with results from an
earlier phase I/II trial of patients with angiomyolipomas, some of
who also had sporadic or TSC-associated LAM, in which
Rapamycin promoted a decrease in the volume of renal
angiomyolipomas by almost 50%, with regrowth to approximately
Figure 1. Rapamycin regulates miRNA in TSC2-deficient LAM patient angiomyolipoma-derived cells. A) Western blot demonstrating
that Rapamycin inhibits phosphorylation of ribosomal protein S6 (S235/236) in TSC2-deficient 621-101 cells. B) Signosis miRNA microarray identifies
Rapamycin-dependent miRNA; boxed dots display an induction of miR-22, 24, and 29b (in green) and a decrease in miR-488 (in red) amongst others
by Rapamycin. The array assays cancer-specific miRNA in duplicate.
doi:10.1371/journal.pone.0060014.g001
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suggest that temporarily slows disease progression, but does not
eradicate the TSC2-deficient LAM and angiomyolipoma cells.
Therapeutic targeting of factors that promote the survival of LAM
cells during Rapamycin therapy could lead to more robust and/or
durable responses.
While miRNA have been studied in many human diseases,
whether miRNA contribute to the therapeutic response to
Figure 2. Exiqon miRNA microarray confirms 8 Rapamycin-dependent miRNA. 621-101 cells were treated with Rapamycin 20 nM or DMSO
for 24 hours. Total RNA was isolated and applied to the Exiqon platform, which assays 946 human miRNA. A) Heat map of miRNA dysregulated by
Rapamycin .1.5-fold, log2 scale. RNA from three biologic replicates per condition was pooled; each miRNA was assayed in quadruplet on the array.
B) miRNA dysregulated by Rapamycin .1.5-fold (normalized to RNU44). Highlighted miRNA (except miR-31 and 210) are common to both the Exiqon
and Signosis platforms. miR-21 is circled.
doi:10.1371/journal.pone.0060014.g002
MicroRNA in TSC and LAM
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e60014Rapamycin in LAM and TSC is unknown. To address this, we
performed two screens to determine whether Rapamycin impacts
miRNA levels in LAM patient angiomyolipoma-derived cells. The
first screen assayed 132 miRNA of known importance to cancer
signaling pathways, while the second was a more comprehensive
screen that assayed all 946 known miRNA listed in miRBase
Version 15.0. The screens revealed a complex and previously
unrecognized network of Rapamycin-regulated miRNA, which we
termed ‘‘RapamiRs’’. Using qRT-PCR to confirm our results, we
demonstrate that miR-21 is significantly induced by Rapamycin,
whereas miR-210 is repressed. We further analyzed Rapamycin’s
effect on miR-21, demonstrating that miR-21 is induced in several
different TSC2-deficient cell lines. Utilizing mouse pre-pericyte
fibroblasts with stable downregulation of tuberin, we confirmed
that the dysregulated expression of miR-21 is mTOR-dependent,
but tuberin independent. Finally, we revealed that the induction of
miR-21 expression by Rapamycin is mediated by post-transcrip-
tional processing of the primary miR-21 transcript, as opposed to
increased transcription. These studies reveal a novel regulatory
network that is upregulated by Rapamycin.
We hypothesize that the upregulation of miR-21 by Rapamycin
in LAM patient-derived cells impacts the therapeutic response to
Rapamycin. First, miR-21 is a known ‘‘oncomiR,’’ inhibiting
multiple tumor suppressor genes, including phosphatase and
tensin homolog (PTEN), programmed cell death 4 (PDCD4) and
sprouty 2 (SPRY2) to promote growth, differentiation and
proliferation [33,34,35,36,37]. These pro-survival effects of miR-
21 may partially explain why there is a resumption of disease upon
treatment discontinuation in LAM patients treated with Rapamy-
cin. Interestingly SPRY2 has previously been shown to regulate
mTORC1 signal transduction and vascularization of the lung
[38]. Second, miR-21 is a known regulator of smooth muscle
morpholology, promoting a de-differentiated state marked by
growth and migration, which is essential for angiogenesis [39,40].
Krymskaya and colleagues have previously demonstrated a role
for regulators of smooth muscle function in the pathogenesis of
LAM, identifying that RhoA is activated in TSC2-deficient cells
[41,42]. Smooth muscle-like LAM cells can be identified in vivo in
two different morphologic states, a highly proliferative ‘‘spindle
shape’’ and a more static ‘‘epithelioid’’ state [43]; the pathways
that regulate the phenotypic switch of LAM cells is unknown.
Figure 3. qRT-PCR confirmation of Rapamycin-dependent miRNA in TSC2-deficient cells. TSC22/2 cells were treated with Rapamycin
20 nM or DMSO for 24 hr and miRNA expression was assessed by qRT-PCR. A) miRNA expression is similar in 621-101 cells using RNU44 (left panel) or
RNU48 (right panel) for normalization. B) miRNA expression in 621-101 cells normalized to RNU44. Highlighted results are significant using a
Bonferroni correction.
doi:10.1371/journal.pone.0060014.g003
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that promotes the survival and metastasis of TSC2-deficient LAM
cells. miR-21 is regulated by inflammatory mediators and in turn
acts to promote inflammation. For example, interleukin-6 is a
potent modulator of miR-21, acting via STAT3 signaling [44].
Additionally, mTORC1 has been shown to activate STAT3
signaling in mice and humans making this an intriguing link
[45,46]. Moreover, miR-21 inhibits PTEN and PDCD4 to repress
NF-kB signaling and IL-10, an anti-inflammatory interleukin [47].
A number of groups have identified a link between innate
immunity pathways and TSC-mTOR signaling. Weichhart and
colleagues have shown that TSC2-deficient cells exhibit an anti-
inflammatory state via the induction of IL-10, whereas Rapamycin
treatment promotes a pro-inflammatory condition by suppressing
Figure 4. miR-21 is mTOR-dependent and may be TSC2-independent. A) Stable downregulation of tuberin in C3H-10T1/2 pre-pericytes
results in increased phosphorylation of ribosomal protein S6, as expected. Treatment with Rapamycin (20 nM, 24 h) inhibits phosphorylation of S6.
B) Downregulation of TSC2 in C3H-10T1/2 cells does not affect miR-21 expression. Inhibition of mTORC1 with Rapamycin induces ,2-fold increase in
miR-21 expression in both control shRNA and TSC2 shRNA cells. Bars represent the mean of two biologic replicates +/2 SD. * p,0.05. C) LAM patient-
derived cells (621-101), TSC2-null rat uterine leiomyoma-derived cells (ELT3), TSC2-null mouse embryonic fibroblasts (MEFs), HEK293 and lung
adenocarcinoma (A549) cells were treated with Rapamycin 20 nM vs Control for 24 h. Relative MiR-21 expression was determined by qRT-PCR.
Human cells were normalized to RNU44, mouse cells to snora202 and rat cells to U87, which are all small nucleolar RNA molecules. For all charts, bars
represent the mean of three biologic replicates +/2 standard error. * p,0.05. ** p,0.01.
doi:10.1371/journal.pone.0060014.g004
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and colleagues have also contributed to the recognition of
inflammatory processes underlying the pathogenesis of LAM,
demonstrating that chemokines and chemokine receptors, espe-
cially CCL-2/MCP-1, are dysregulated in LAM cells and in
bronchoalveolar lavage fluid obtained from LAM patients [49].
Therefore, the induction of miR-21 by Rapamycin may induce a
proliferative smooth muscle morphology and contribute to a pro-
inflammatory milieu.
Our identification of Rapamycin-induced miRNA reveals a
novel and complex signaling network downstream of mTOR with
potential therapeutic implications for women with LAM and
Figure 5. Rapamycin induces miR-21 expression via an AKT-independent mechanism. A) Western blot analysis of 621-101 cells treated
with DMSO (lane 1), Rapamycin (20 nM, 24 h - lane 2), the AKT inhibitor MK2206 (10 nM, 24 h - lane 3), and Rapamycin and MK2206 (lane 4).
Rapamycin treatment induces AKT phosphorylation at S473 and MK2206 abrogates Rapamycin’s effect on phosphor-Akt. B) Expression of miR-21, 24,
29b, and 221 in 621-101 cells treated as in A). miR-21 levels are induced by Rapamycin, however the addition of MK2206 has no effect suggesting an
AKT-independent mechanism.
doi:10.1371/journal.pone.0060014.g005
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miR-21 induction by Rapamycin proves to be a strong pro-
survival stimulus in TSC2-deficient cells cells, then suppression of
miR-21 in conjunction with Rapamycin could represent an
effective therapeutic strategy for TSC and LAM. Manipulation
of miRNA expression is currently being studied as a therapy for
malignancies and cardiomyopathies, with promising results in
multiple pre-clinical models of disease [50,51]; ‘antagomiRs’ that
Figure 6. Rapamycin promotes the post-transcriptional processing of pre-miR-21. A) The biogenesis of mature miR-21. Pri-miR is
transcribed from the intronic region of the TMEM49 gene and processed into pre-miR-21 by the Drosha/Pasha complex and further processed by
Dicer to create the mature form. B) 621-101 cells were treated with Rapamycin 20 nM or control (DMSO) for 24 hours. Total RNA was extracted and
assayed by qRT-PCR for the differential expression of pri-miR-21, pre-miR-21 and miR-21. Expression of pre-miR-21 was significantly induced by
Rapamycin, whereas pri-miR-21 levels were not affected, suggesting that Rapamycin promotes the Drosha-mediated post-transcriptional processing
of pri-miR-21 into pre-miR-21 at 24 hours. Bars represent the mean of three biological replicates +/2 SD. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0060014.g006
MicroRNA in TSC and LAM
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RapamiRs may also be useful as serum biomarkers of response to
Rapamycin. Finally, our findings may be relevant to other diseases
in which Rapamycin and its analogs are currently being used
therapeutically, including cancer, for which there are currently
more than 100 active cancer clinical trials using mTOR inhibitors.
Methods
Cell culture and Tsc2-downregulation
621-101 (The Rothberg Institute), Tsc2-null mouse embryonic
fibroblasts (provided by Dr. David Kwiatkowski), HEK293,
C3H10T1/2 cells (American Type Culture Collection) and
ELT3 cells (provided by Dr. Cheryl Walker) were maintained in
DMEM supplemented with 10% FBS (Sigma), Penicillin (50
units/mL) and Streptomycin (50 mg/mL); media for ELT3 cells
also contained G418 (0.5 mg/mL). Lentiviral particles expressing
shTSC2 were generated by transfecting HEK293T cells with
plasmid DNA expressing shTSC2 (or empty vector) and lentiviral
packaging particles (VSVG, PLP1, PLP2). Supernatant containing
virions was applied to C3H10T1/2 cells (passage 7) for infection.
C3H10T1/2 with lentiviral transfection were maintained in
DMEM supplemented with 10% FBS (Sigma) with Puromycin
(for selection).
Immunoblot analyses
Lysates were mixed with Laemmli Sample buffer and boiled for
10 minutes. 30 mg of sample were resolved in a 4–12% acrylamide
gel and transferred to nitrocellulose membranes (Bio-Rad,
Hercules, CA). The membranes were blotted overnight with
rabbit anti–phospho-S235/236 S6 ribosomal protein (Cell Signal-
ing), mouse anti-Actin (Sigma-Aldrich), or rabbit anti-Tuberin
(Santa Cruz Biotechnology Inc.).
MicroRNA Screens
621-101 cells were grown in DMEM supplemented with 10%
FBS until 60% confluent. Cells were then treated for 24 hours
with Rapamycin (20 nM) or equal volume Dimethylsulfoxide
(DMSO). Cells were washed twice with phosphate buffered saline
and RNA extracted using the miRCURY RNA Isolation Kit
(Exiqon). Assaying of microRNA was performed on the Signosis
Cancer MicroRNA Array platform and the miRCURY LNA 5
th
generation microRNA microarray platform (Exiqon), which
contained capture probes for all miRNAs annotated in miRBase
(version 15.0; http://www.mirbase.org/).
Real-time quantitative Reverse Transcription -
Polymerase Chain Reaction Analysis (qRT-PCR)
Total RNA was extracted using the miRCURY RNA Isolation
Kit (Exiqon). For miRNA quantification RNA was reverse-
transcribed using a Taq- ManTM microRNA reverse transcrip-
tion kit, and subjected to real-time PCR using TaqManTM
microRNA assay kits (Applied Biosystems). Reactions were
performed in triplicate, using an Applied Biosystems Step One
Plus instrument. MiRNA expression was normalized to small
nuclear RNA (snRNA) RNU44 or RNU48. For quantification of
pri-miR-21 and pre-miR-21, total RNA was reverse transcribed
and Quantitative PCR was performed using a SYBR-green kit
(Applied Biosystems). The following primers were used to assay
pre-miR-21: 59- TGTCGGGTAGCTTATCAGAC-39 (forward),
59- TGTCAGACAGCCCATCGACT-39 (reverse). The following
primers were used to assay pre-miR-21: 59-
TTTTGTTTTGCTTGGGAGGA-39 (forward), 59- AGCAGA-
CAGTCAGGCAGGAT-39 (reverse). Assays were performed
using three biologic replicates and three technical replicates for
each treatment condition. Assays were performed on the Applied
Biosystems Step One Plus instrument. Only one PCR product was
observed for each assay.
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